Skye Bioscience's Investigational Drug Disappoints As Monotherapy For Weight Loss - Skye Bioscience (NASDAQ:SKYE)

Skye Bio Obesity Drug Fails in Phase 2; Hopes Now Ride on Higher Doses and Combo Treatment

While Skye Bioscience said its drug nimacimab may yet achieve better weight loss results with higher doses, the company and analysts are interested in the drug’s potential to be combined with Novo Nordisk’s Wegovy. Skye’s drug is an antibody designed to preferentially target CB1 receptors in the gut, offering an alternative approach to activating GLP-1 receptors. The post Skye Bio Obesity Drug Fails in Phase 2; Hopes Now Ride on Higher Doses and…

Skye Bioscience's Investigational Drug Disappoints As Monotherapy For Weight Loss - Skye Bioscience (NASDAQ:SKYE)

Skye Bioscience Inc. (NASDAQ:SKYE) stock sank on Monday after the company released topline data from its 26-week Phase 2a CBeyond proof-of-concept study of nimacimab. The nimacimab monotherapy arm did not achieve the primary endpoint of weight loss compared to placebo (-1.52% vs. -0.26 for placebo, mITT). Preliminary pharmacokinetic analysis showed lower than expected drug exposure of nimacimab, supporting evaluation of higher dosing. Also Read:…

Skye plummets 60% on mid-stage data for nimacimab for weight loss

Skye Biosciences' nimacimab missed weight loss targets in phase 2a, but showed promise when given with Novo Nordisk's Wegovy. Read more here.

Skye’s obesity drug fails in mid-stage study

The drug, nimacimab, did not outperform placebo on its own, but the company said that it appeared to boost weight loss when used with Wegovy.

Skye Bioscience Reports Topline CBeyond™ Phase 2a Data from Nimacimab Monotherapy and Combination Clinical Trial

Nimacimab monotherapy did not meet its primary endpoint for weight loss; preliminary pharmacokinetic analysis showed lower than expected drug exposure,...

Skye’s cannabinoid drug fails in mid-stage obesity trial

Skye Bioscience’s obesity shot has failed in a mid-stage trial, adding to the evidence that cannabinoid receptor 1 inhibitors have little effect in the disease. Nimacimab, as Skye’s antibody is known, did not improve weight ...